Is Immunovant, Inc. (IMVT) Halal?
Shariah Screening — 5 Standards
Based on financial data from March 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 13.2% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 13.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 92.0% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 13.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 92.0% / 33% | 0.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -69.3% | |
| Return on Assets (ROA) | -41.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$376M |
| Free Cash Flow | -$377M |
| Total Debt | $98,000 |
| Current Ratio | 15.7 |
| Total Assets | $776M |
Price & Trading
| Last Close | $25.36 |
| 50-Day MA | $25.91 |
| 200-Day MA | $21.00 |
| Avg Volume | 1.4M |
| Beta | 0.6 |
|
52-Week Range
$12.72
| |
About Immunovant, Inc. (IMVT)
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Immunovant, Inc. (IMVT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Immunovant, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Immunovant, Inc.'s debt ratio?
Immunovant, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Immunovant, Inc.'s key financial metrics?
Immunovant, Inc. has a market capitalization of $4.9B. Return on equity stands at -69.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.